Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB. #Table 4 (R-2-butyl)
Nichols, DE. Structure-activity relationships of serotonin 5-HT2A agonists WIREs Membr. Transp. Signal, 1 Sep 2012, 1 (5), 559-579. 573 kB. https://doi.org/10.1002/wmts.42 #17
Nichols, DE. LSD and its lysergamide cousins Heffter Rev., 1 Jan 2001, 2 (6), 80–87. 265 kB.
Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. 3.9 MB. #25 In German. MS,NMR,IR
McCorvy, JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics Ph. D. Thesis, Purdue University, 1 Jan 2012. 3.9 MB. #(R) LASBA
Clark, CC. The differentiation of lysergic acid diethylamide (LSD) from N-methyl-N-propyl and N-butyl amides of lysergic acid J. Forensic Sci., 1 May 1989, 34 (3), 532–546. 445 kB. https://doi.org/10.1520/JFS12674J #VIIA-1,VIIA-2,VIIB-1,VIIB-2 LC,MS,TLC
Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes J. Med. Chem., 1 Mar 1995, 38 (6), 958–966. 1.2 MB. https://doi.org/10.1021/jm00006a015 #2a MS,NMR,IR,TLC,other